G

GH Research PLC
NASDAQ:GHRS

Watchlist Manager
GH Research PLC
NASDAQ:GHRS
Watchlist
Price: 9.27 USD -3.64% Market Closed
Market Cap: 482.3m USD
Have any thoughts about
GH Research PLC?
Write Note

GH Research PLC
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

GH Research PLC
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
G
GH Research PLC
NASDAQ:GHRS
Accrued Liabilities
$2.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Perrigo Company PLC
NYSE:PRGO
Accrued Liabilities
$533.1m
CAGR 3-Years
-3%
CAGR 5-Years
-6%
CAGR 10-Years
0%
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Accrued Liabilities
$858m
CAGR 3-Years
14%
CAGR 5-Years
29%
CAGR 10-Years
18%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Accrued Liabilities
$34.6m
CAGR 3-Years
53%
CAGR 5-Years
23%
CAGR 10-Years
20%
Cosmo Pharmaceuticals NV
SIX:COPN
Accrued Liabilities
€5.3m
CAGR 3-Years
74%
CAGR 5-Years
49%
CAGR 10-Years
33%
Ovoca Bio PLC
LSE:OVB
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

GH Research PLC
Glance View

Market Cap
482.3m USD
Industry
Pharmaceuticals

GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 9 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The company focuses on developing its 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), therapies for the treatment of patients with Treatment-Resistant Depression (TRD). Its portfolio includes GH001, its inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, its injectable 5-MeO-DMT product candidate. The firm is developing its 5-MeO-DMT product candidates, GH001 and GH002, in its focus area of psychiatric and neurological disorders. Its lead program, GH001, is in the Phase II part of an ongoing Phase I/II clinical trial in patients with TRD. The 5-MeO-DMT is a serotonergic psychedelic, a class of psychoactive drugs that act through an agonist action on serotonin receptors and cause an altered state of consciousness.

GHRS Intrinsic Value
4.27 USD
Overvaluation 54%
Intrinsic Value
Price
G

See Also

What is GH Research PLC's Accrued Liabilities?
Accrued Liabilities
2.3m USD

Based on the financial report for Dec 31, 2023, GH Research PLC's Accrued Liabilities amounts to 2.3m USD.

What is GH Research PLC's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 1Y
-3%

Over the last year, the Accrued Liabilities growth was -3%.

Back to Top